SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Drug Regulation

PUBLISHER: Meticulous Research | PRODUCT CODE: 2149773

Cover Image

PUBLISHER: Meticulous Research | PRODUCT CODE: 2149773

Pharmacovigilance Software Market Size, Share, and Industry Analysis by Functionality, Component, Deployment Mode, Organization Size, End User, and Geography - Global Forecast to 2036

PUBLISHED:
PAGES: 228 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4175
PDF & Excel (Multi User License)
USD 5875
PDF & Excel (Global Site License)
USD 7875

Add to Cart

Description

Table of Contents

List of Tables

The global Pharmacovigilance Software Market was valued at USD 1,260.0 million in 2025. It is estimated to reach USD 1,397.3 million in 2026 and is projected to grow to USD 3,398.1 million by 2036, at a CAGR of 9.3% during the forecast period. This report offers a detailed look at the market, covering the regulatory landscape, the technology landscape, the value chain, investment, partnership, and M&A activity, case studies, competitive activity, and future growth opportunities.

Pharmacovigilance software is used to collect, process, assess, and report adverse events and to monitor the safety of medicinal products and medical devices throughout their lifecycle. It includes adverse event case management, signal detection and management, aggregate and periodic reporting, risk management, literature and social media monitoring, and safety analytics and AI automation, delivered as software and services to pharmaceutical and biotechnology companies, CROs, device manufacturers, and regulators.

The FDA transition to the ICH E2B(R3) standard in 2026, rising adverse event case volumes, and the migration of safety systems to the cloud are driving demand, while vendors are introducing generative and agentic AI and the market is consolidating, as shown by the agreement of Dassault Systemes to acquire ArisGlobal in July 2026. At the same time, implementation and validation costs and legacy lock-in shape the pace of change.

The report examines market drivers, restraints, opportunities, challenges, and trends, the regulatory landscape in the U.S., the EU, the U.K., Japan, China, and India, the technology landscape, the value chain, Porter's five forces, investment, partnership, and M&A activity, and case studies. It explains why safety analytics and AI automation, cloud deployment, SMEs, and biotechnology companies and CROs are growing faster than the overall market. It also provides market forecasts, segment-level insights, and regional analysis across 5 regions and 27 countries and sub-regions to support business, investment, and product decisions.

Market Dynamics

Expanding regulatory reporting requirements, led by the FDA transition to E2B(R3), are the main force behind market growth. Rising adverse event case volumes, the growth of biotechnology pipelines, and the migration of safety systems to the cloud reinforce demand.

High implementation and validation costs and legacy system lock-in slow the pace of adoption and platform change. In addition, the validation and regulatory acceptance of AI, data privacy and residency requirements, and shortages of skilled PV and technology staff remain challenges.

AI-driven automation of case processing, demand from small and mid-sized biopharmaceutical companies, and the development of PV systems in emerging markets offer significant opportunities. Meanwhile, generative and agentic AI is entering production use, safety software is being consolidated into broader platforms, and real-world data is being integrated into signal detection.

Segment Analysis

The report analyzes the market by functionality, component, deployment mode, organization size, end user, and geography, helping stakeholders identify the most promising growth opportunities.

Based on functionality, the market is segmented into adverse event case management, signal detection and management, aggregate and periodic reporting, risk management, literature and social media monitoring, and safety analytics and AI automation. In 2026, adverse event case management is expected to account for the largest share of the market, while safety analytics and AI automation is expected to grow the fastest.

Based on component, the market is segmented into software and services. In 2026, software is expected to account for the larger share of the market and to grow faster, driven by cloud subscriptions and AI modules.

Based on deployment mode, the market is segmented into cloud-based and on-premises. In 2026, cloud-based deployment is expected to account for the larger share and to grow faster, as legacy systems migrate to SaaS platforms.

Based on organization size, the market is segmented into large enterprises and small and mid-sized enterprises. In 2026, large enterprises are expected to hold the larger share, while SMEs are expected to grow faster, supported by affordable pre-configured cloud solutions.

Based on end user, the market is segmented into pharmaceutical companies, biotechnology companies, CROs and PV outsourcing providers, medical device manufacturers, and regulatory authorities and others. In 2026, pharmaceutical companies are expected to hold the largest share, while biotechnology companies and CROs are expected to grow the fastest.

Regional Analysis

The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, spanning 27 countries and sub-regions. The regional analysis considers PV regulations, pharmaceutical and biotechnology industry structure, cloud readiness, data residency rules, and outsourcing activity.

In 2026, North America is expected to account for the largest share of the global market, driven by the size of the U.S. industry and the FDA transition to E2B(R3), with the U.S. as the largest country market in the world. In Europe, the U.K. is the largest market, slightly ahead of Germany.

Asia-Pacific is expected to grow the fastest during the forecast period, led by India, the fastest-growing country market in the world, while Japan is the largest market in the region and the second-largest in the world. In the Middle East & Africa, Israel is the largest market and Saudi Arabia is the fastest-growing, while in Latin America, Brazil is the largest market and Mexico is expected to grow the fastest.

Competitive Landscape

The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard, and market share analysis, together with profiles of leading companies including their financial performance, product portfolios, strategy and market position, strategic developments, and SWOT analyses.

The market is led by a small group of platform vendors. Based on 2025 market share, Oracle ranked first, followed by Veeva Systems, ArisGlobal, IQVIA, Qinecsa Solutions, and Ennov. Product launches and agreements and contracts are the main strategies, including agentic AI launches by ArisGlobal, Veeva, Oracle, and RxLogix, the go-live of UCB on the Veeva Safety Suite, and the agreement of Dassault Systemes to acquire ArisGlobal.

The competitive benchmarking compares companies across functionalities, deployment models, and end users. Companies compete on cloud delivery, AI capabilities, platform breadth, migration support, validation, and price.

Key companies profiled in the report include Oracle Corporation (U.S.), Veeva Systems Inc. (U.S.), ArisGlobal LLC (U.S.), IQVIA Holdings Inc. (U.S.), Ennov (France), AB Cube (France), RxLogix Corporation (U.S.), Qinecsa Solutions (U.K.), Sarjen Systems Pvt. Ltd. (India), Clinevo Technologies (India), Cloudbyz (U.S.), and Biologit (Ireland).

How This Report Helps

  • Provides reliable market size estimates and long-term forecasts for the global pharmacovigilance software market.
  • Explains how E2B(R3) and other regulatory requirements, case volumes, cloud migration, and AI affect market growth.
  • Identifies high-growth opportunities across functionality, component, deployment mode, organization size, end user, and region.
  • Analyzes the regulatory and technology landscapes, the value chain, and investment and M&A activity shaping the market.
  • Benchmarks leading companies based on their portfolios and market share.
  • Supports product strategy, partnership and acquisition evaluation, investment planning, and market entry decisions.
  • Delivers practical market insights for PV software vendors, implementation partners, pharmaceutical and biotechnology companies, CROs, device manufacturers, and investors.

Key Questions Answered

  • How big is the global pharmacovigilance software market today, and how will it grow through 2036?
  • How is the FDA transition to E2B(R3) driving demand for safety database upgrades and migrations?
  • What are the main drivers, restraints, opportunities, and challenges shaping the industry?
  • Which functionality, component, deployment mode, organization size, end-user, and regional segments will grow the fastest?
  • How will AI automation change case processing and the structure of PV spending?
  • How fast will safety systems move from on-premises to cloud platforms?
  • Which regions and countries offer the most attractive business opportunities?
  • Who are the leading companies in the market, and what strategies are they following?
  • How will platform consolidation, including the Dassault Systemes-ArisGlobal deal, reshape the competitive landscape?
Show more
Product Code: MRHC - 1042043

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition & Scope
  • 1.2. Market Ecosystem
  • 1.3. Currency & Limitations
    • 1.3.1. Currency
    • 1.3.2. Limitations
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Approach
  • 2.2. Data Collection & Validation Process
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research & Validation
      • 2.2.2.1. Primary Interviews with Industry Experts
      • 2.2.2.2. Country-/Region-Level Analysis
  • 2.3. Market Estimation
    • 2.3.1. Bottom-Up Approach
    • 2.3.2. Top-Down Approach
    • 2.3.3. Forecast Methodology
  • 2.4. Data Triangulation
  • 2.5. Assumptions

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Dynamics & Impact Analysis
    • 4.2.1. Drivers
      • 4.2.1.1. Expanding Regulatory Reporting Requirements
      • 4.2.1.2. Rising Adverse Event Case Volumes
      • 4.2.1.3. Growth of Biotechnology and New Product Pipelines
      • 4.2.1.4. Migration of Safety Systems to the Cloud
    • 4.2.2. Restraints
      • 4.2.2.1. High Implementation and Validation Costs
      • 4.2.2.2. Legacy System Lock-in and Migration Complexity
    • 4.2.3. Opportunities
      • 4.2.3.1. AI-Driven Automation of Case Processing
      • 4.2.3.2. Demand from Small and Mid-Sized Biopharmaceutical Companies
      • 4.2.3.3. Development of PV Systems in Emerging Markets
    • 4.2.4. Challenges
      • 4.2.4.1. Validation and Regulatory Acceptance of AI
      • 4.2.4.2. Data Privacy and Residency Requirements
      • 4.2.4.3. Shortages of Skilled PV and Technology Staff
    • 4.2.5. Trends
      • 4.2.5.1. Generative and Agentic AI in Safety Operations
      • 4.2.5.2. Consolidation of Safety, Regulatory, and Quality Platforms
      • 4.2.5.3. Integration of Real-World Data into Signal Detection
  • 4.3. Regulatory Landscape
    • 4.3.1. United States
    • 4.3.2. European Union
    • 4.3.3. United Kingdom
    • 4.3.4. Japan
    • 4.3.5. China
    • 4.3.6. India and Other Markets
  • 4.4. Technology Landscape
    • 4.4.1. Safety Databases and Coding Standards
    • 4.4.2. Automation and AI
    • 4.4.3. Signal Detection Methods
    • 4.4.4. Cloud Delivery and Validation
    • 4.4.5. Integration and Real-World Data
    • 4.4.6. Security, Auditability, and Quality Management
  • 4.5. Value Chain Analysis
    • 4.5.1. Standards, Dictionaries, and Technology Components
    • 4.5.2. Software Vendors
    • 4.5.3. Implementation Partners and Outsourcing Providers
    • 4.5.4. End Users and Regulators
  • 4.6. Porter's Five Forces Analysis
    • 4.6.1. Threat of New Entrants: Low to Medium
    • 4.6.2. Bargaining Power of Suppliers: Low to Medium
    • 4.6.3. Bargaining Power of Buyers: Medium
    • 4.6.4. Threat of Substitutes: Low to Medium
    • 4.6.5. Competitive Rivalry: Medium to High
  • 4.7. Investment, Partnership & M&A Analysis
    • 4.7.1. Platform Consolidation
    • 4.7.2. AI Investment
    • 4.7.3. Cloud Platform Expansion
  • 4.8. Case Studies
    • 4.8.1. Dassault Systemes and ArisGlobal: Consolidation of a Safety Platform
    • 4.8.2. EPS Corporation: CRO Adoption of a Multi-Tenant Safety Platform
    • 4.8.3. Merck: Integrated Safety on a Unified Platform
    • 4.8.4. Industry Transition to E2B(R3) in the U.S.

5. Pharmacovigilance Software Market, by Functionality

  • 5.1. Introduction
  • 5.2. Adverse Event Case Management
  • 5.3. Signal Detection & Management
  • 5.4. Aggregate & Periodic Reporting
  • 5.5. Risk Management
  • 5.6. Literature & Social Media Monitoring
  • 5.7. Safety Analytics & AI Automation

6. Pharmacovigilance Software Market, by Component

  • 6.1. Introduction
  • 6.2. Software
  • 6.3. Services

7. Pharmacovigilance Software Market, by Deployment Mode

  • 7.1. Introduction
  • 7.2. Cloud-Based
  • 7.3. On-Premises

8. Pharmacovigilance Software Market, by Organization Size

  • 8.1. Introduction
  • 8.2. Large Enterprises
  • 8.3. Small & Mid-Sized Enterprises

9. Pharmacovigilance Software Market, by End User

  • 9.1. Introduction
  • 9.2. Pharmaceutical Companies
  • 9.3. Biotechnology Companies
  • 9.4. CROs & PV Outsourcing Providers
  • 9.5. Medical Device Manufacturers
  • 9.6. Regulatory Authorities & Others

10. Pharmacovigilance Software Market, by Geography

  • 10.1. Introduction
  • 10.2. North America
    • 10.2.1. U.S.
    • 10.2.2. Canada
  • 10.3. Europe
    • 10.3.1. Germany
    • 10.3.2. U.K.
    • 10.3.3. France
    • 10.3.4. Switzerland
    • 10.3.5. Italy
    • 10.3.6. Spain
    • 10.3.7. Netherlands
    • 10.3.8. Nordic Countries
    • 10.3.9. Belgium
    • 10.3.10. Rest of Europe
  • 10.4. Asia-Pacific
    • 10.4.1. Japan
    • 10.4.2. China
    • 10.4.3. India
    • 10.4.4. South Korea
    • 10.4.5. Australia
    • 10.4.6. Singapore
    • 10.4.7. Rest of Asia-Pacific
  • 10.5. Latin America
    • 10.5.1. Brazil
    • 10.5.2. Mexico
    • 10.5.3. Rest of Latin America
  • 10.6. Middle East & Africa
    • 10.6.1. Israel
    • 10.6.2. Saudi Arabia
    • 10.6.3. UAE
    • 10.6.4. South Africa
    • 10.6.5. Rest of Middle East & Africa

11. Competitive Landscape

  • 11.1. Overview
  • 11.2. Key Growth Strategies
  • 11.3. Competitive Benchmarking
  • 11.4. Competitive Dashboard
    • 11.4.1. Industry Leaders
    • 11.4.2. Market Differentiators
    • 11.4.3. Vanguards
    • 11.4.4. Emerging Companies
  • 11.5. Market Share Analysis, by Key Player (2025)

12. Company Profiles

  • 12.1. Oracle Corporation
    • 12.1.1. Business Overview
    • 12.1.2. Financial Overview
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategy and Market Position
    • 12.1.5. Strategic Developments
    • 12.1.6. SWOT Analysis
  • 12.2. Veeva Systems Inc.
    • 12.2.1. Business Overview
    • 12.2.2. Financial Overview
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategy and Market Position
    • 12.2.5. Strategic Developments
    • 12.2.6. SWOT Analysis
  • 12.3. ArisGlobal LLC
    • 12.3.1. Business Overview
    • 12.3.2. Financial Overview
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategy and Market Position
    • 12.3.5. Strategic Developments
    • 12.3.6. SWOT Analysis
  • 12.4. IQVIA Holdings Inc.
    • 12.4.1. Business Overview
    • 12.4.2. Financial Overview
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategy and Market Position
    • 12.4.5. Strategic Developments
    • 12.4.6. SWOT Analysis
  • 12.5. Ennov
    • 12.5.1. Business Overview
    • 12.5.2. Financial Overview
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategy and Market Position
    • 12.5.5. Strategic Developments
    • 12.5.6. SWOT Analysis
  • 12.6. AB Cube
    • 12.6.1. Business Overview
    • 12.6.2. Financial Overview
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategy and Market Position
    • 12.6.5. Strategic Developments
    • 12.6.6. SWOT Analysis
  • 12.7. RxLogix Corporation
    • 12.7.1. Business Overview
    • 12.7.2. Financial Overview
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategy and Market Position
    • 12.7.5. Strategic Developments
    • 12.7.6. SWOT Analysis
  • 12.8. Qinecsa Solutions
    • 12.8.1. Business Overview
    • 12.8.2. Financial Overview
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategy and Market Position
    • 12.8.5. Strategic Developments
    • 12.8.6. SWOT Analysis
  • 12.9. Sarjen Systems Pvt. Ltd.
    • 12.9.1. Business Overview
    • 12.9.2. Financial Overview
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategy and Market Position
    • 12.9.5. Strategic Developments
    • 12.9.6. SWOT Analysis
  • 12.10. Clinevo Technologies
    • 12.10.1. Business Overview
    • 12.10.2. Financial Overview
    • 12.10.3. Product Portfolio
    • 12.10.4. Strategy and Market Position
    • 12.10.5. Strategic Developments
    • 12.10.6. SWOT Analysis
  • 12.11. Cloudbyz
    • 12.11.1. Business Overview
    • 12.11.2. Financial Overview
    • 12.11.3. Product Portfolio
    • 12.11.4. Strategy and Market Position
    • 12.11.5. Strategic Developments
    • 12.11.6. SWOT Analysis
  • 12.12. Biologit
    • 12.12.1. Business Overview
    • 12.12.2. Financial Overview
    • 12.12.3. Product Portfolio
    • 12.12.4. Strategy and Market Position
    • 12.12.5. Strategic Developments
    • 12.12.6. SWOT Analysis

13. Appendix

  • 13.1. Customization Options
  • 13.2. Available Related Reports
Show more
Product Code: MRHC - 1042043

LIST OF TABLES

List of Tables

  • Table 1. Pharmacovigilance Software Market: Scope and Segmentation
  • Table 2. Pharmacovigilance Software Market: Scope Boundaries
  • Table 3. Pharmacovigilance Software Market: Average Annual Exchange Rates Used (per USD)
  • Table 4. Key Pharmacovigilance Regulatory Requirements Affecting PV Software
  • Table 5. PV Software Technology Components and Trends
  • Table 6. Porter's Five Forces Analysis: Summary
  • Table 7. Selected Developments in the Pharmacovigilance Software Market
  • Table 8. Pharmacovigilance Software Market: Functionality Comparison
  • Table 9. Global Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 10. Pharmacovigilance Software Market for Adverse Event Case Management, by Country/Region, 2024-2036 (USD Million)
  • Table 11. Pharmacovigilance Software Market for Signal Detection & Management, by Country/Region, 2024-2036 (USD Million)
  • Table 12. Pharmacovigilance Software Market for Aggregate & Periodic Reporting, by Country/Region, 2024-2036 (USD Million)
  • Table 13. Pharmacovigilance Software Market for Risk Management, by Country/Region, 2024-2036 (USD Million)
  • Table 14. Pharmacovigilance Software Market for Literature & Social Media Monitoring, by Country/Region, 2024-2036 (USD Million)
  • Table 15. Pharmacovigilance Software Market for Safety Analytics & AI Automation, by Country/Region, 2024-2036 (USD Million)
  • Table 16. Pharmacovigilance Software Market: Component Scope
  • Table 17. Global Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 18. Pharmacovigilance Software Market for Software, by Country/Region, 2024-2036 (USD Million)
  • Table 19. Pharmacovigilance Software Market for Services, by Country/Region, 2024-2036 (USD Million)
  • Table 20. Pharmacovigilance Software Market: Deployment Mode Comparison
  • Table 21. Global Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 22. Pharmacovigilance Software Market for Cloud-Based, by Country/Region, 2024-2036 (USD Million)
  • Table 23. Pharmacovigilance Software Market for on-Premises, by Country/Region, 2024-2036 (USD Million)
  • Table 24. Pharmacovigilance Software Market: Organization Size Comparison
  • Table 25. Global Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 26. Pharmacovigilance Software Market for Large Enterprises, by Country/Region, 2024-2036 (USD Million)
  • Table 27. Pharmacovigilance Software Market for Small & Mid-Sized Enterprises, by Country/Region, 2024-2036 (USD Million)
  • Table 28. Pharmacovigilance Software Market: End User Comparison
  • Table 29. Global Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 30. Pharmacovigilance Software Market for Pharmaceutical Companies, by Country/Region, 2024-2036 (USD Million)
  • Table 31. Pharmacovigilance Software Market for Biotechnology Companies, by Country/Region, 2024-2036 (USD Million)
  • Table 32. Pharmacovigilance Software Market for CROs & PV Outsourcing Providers, by Country/Region, 2024-2036 (USD Million)
  • Table 33. Pharmacovigilance Software Market for Medical Device Manufacturers, by Country/Region, 2024-2036 (USD Million)
  • Table 34. Pharmacovigilance Software Market for Regulatory Authorities & Others, by Country/Region, 2024-2036 (USD Million)
  • Table 35. Global Pharmacovigilance Software Market, by Region, 2024-2036 (USD Million)
  • Table 36. North America Pharmacovigilance Software Market, by Country, 2024-2036 (USD Million)
  • Table 37. North America Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 38. North America Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 39. North America Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 40. North America Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 41. North America Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 42. U.S. Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 43. U.S. Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 44. U.S. Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 45. U.S. Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 46. U.S. Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 47. Canada Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 48. Canada Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 49. Canada Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 50. Canada Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 51. Canada Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 52. Europe Pharmacovigilance Software Market, by Country, 2024-2036 (USD Million)
  • Table 53. Europe Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 54. Europe Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 55. Europe Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 56. Europe Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 57. Europe Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 58. Germany Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 59. Germany Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 60. Germany Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 61. Germany Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 62. Germany Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 63. U.K. Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 64. U.K. Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 65. U.K. Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 66. U.K. Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 67. U.K. Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 68. France Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 69. France Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 70. France Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 71. France Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 72. France Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 73. Switzerland Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 74. Switzerland Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 75. Switzerland Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 76. Switzerland Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 77. Switzerland Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 78. Italy Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 79. Italy Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 80. Italy Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 81. Italy Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 82. Italy Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 83. Spain Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 84. Spain Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 85. Spain Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 86. Spain Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 87. Spain Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 88. Netherlands Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 89. Netherlands Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 90. Netherlands Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 91. Netherlands Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 92. Netherlands Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 93. Nordic Countries Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 94. Nordic Countries Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 95. Nordic Countries Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 96. Nordic Countries Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 97. Nordic Countries Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 98. Belgium Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 99. Belgium Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 100. Belgium Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 101. Belgium Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 102. Belgium Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 103. Rest of Europe Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 104. Rest of Europe Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 105. Rest of Europe Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 106. Rest of Europe Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 107. Rest of Europe Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 108. Asia-Pacific Pharmacovigilance Software Market, by Country, 2024-2036 (USD Million)
  • Table 109. Asia-Pacific Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 110. Asia-Pacific Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 111. Asia-Pacific Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 112. Asia-Pacific Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 113. Asia-Pacific Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 114. Japan Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 115. Japan Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 116. Japan Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 117. Japan Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 118. Japan Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 119. China Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 120. China Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 121. China Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 122. China Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 123. China Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 124. India Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 125. India Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 126. India Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 127. India Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 128. India Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 129. South Korea Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 130. South Korea Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 131. South Korea Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 132. South Korea Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 133. South Korea Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 134. Australia Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 135. Australia Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 136. Australia Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 137. Australia Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 138. Australia Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 139. Singapore Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 140. Singapore Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 141. Singapore Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 142. Singapore Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 143. Singapore Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 144. Rest of Asia-Pacific Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 145. Rest of Asia-Pacific Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 146. Rest of Asia-Pacific Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 147. Rest of Asia-Pacific Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 148. Rest of Asia-Pacific Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 149. Latin America Pharmacovigilance Software Market, by Country, 2024-2036 (USD Million)
  • Table 150. Latin America Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 151. Latin America Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 152. Latin America Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 153. Latin America Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 154. Latin America Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 155. Brazil Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 156. Brazil Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 157. Brazil Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 158. Brazil Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 159. Brazil Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 160. Mexico Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 161. Mexico Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 162. Mexico Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 163. Mexico Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 164. Mexico Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 165. Rest of Latin America Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 166. Rest of Latin America Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 167. Rest of Latin America Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 168. Rest of Latin America Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 169. Rest of Latin America Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 170. Middle East & Africa Pharmacovigilance Software Market, by Country, 2024-2036 (USD Million)
  • Table 171. Middle East & Africa Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 172. Middle East & Africa Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 173. Middle East & Africa Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 174. Middle East & Africa Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 175. Middle East & Africa Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 176. Israel Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 177. Israel Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 178. Israel Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 179. Israel Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 180. Israel Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 181. Saudi Arabia Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 182. Saudi Arabia Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 183. Saudi Arabia Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 184. Saudi Arabia Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 185. Saudi Arabia Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 186. UAE Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 187. UAE Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 188. UAE Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 189. UAE Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 190. UAE Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 191. South Africa Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 192. South Africa Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 193. South Africa Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 194. South Africa Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 195. South Africa Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 196. Rest of Middle East & Africa Pharmacovigilance Software Market, by Functionality, 2024-2036 (USD Million)
  • Table 197. Rest of Middle East & Africa Pharmacovigilance Software Market, by Component, 2024-2036 (USD Million)
  • Table 198. Rest of Middle East & Africa Pharmacovigilance Software Market, by Deployment Mode, 2024-2036 (USD Million)
  • Table 199. Rest of Middle East & Africa Pharmacovigilance Software Market, by Organization Size, 2024-2036 (USD Million)
  • Table 200. Rest of Middle East & Africa Pharmacovigilance Software Market, by End User, 2024-2036 (USD Million)
  • Table 201. Key Growth Strategies and Examples (January 2024-July 2026)
  • Table 202. Pharmacovigilance Software Market: Competitive Benchmarking
  • Table 203. Pharmacovigilance Software Market: Market Share and Rank, by Key Player (2025)
  • Table 204. Oracle Corporation: Product Portfolio
  • Table 205. Oracle Corporation: Strategic Developments
  • Table 206. Veeva Systems Inc.: Product Portfolio
  • Table 207. Veeva Systems Inc.: Strategic Developments
  • Table 208. ArisGlobal LLC: Product Portfolio
  • Table 209. ArisGlobal LLC: Strategic Developments
  • Table 210. IQVIA Holdings Inc.: Product Portfolio
  • Table 211. IQVIA Holdings Inc.: Strategic Developments
  • Table 212. Ennov: Product Portfolio
  • Table 213. Ennov: Strategic Developments
  • Table 214. AB Cube: Product Portfolio
  • Table 215. AB Cube: Strategic Developments
  • Table 216. RxLogix Corporation: Product Portfolio
  • Table 217. RxLogix Corporation: Strategic Developments
  • Table 218. Qinecsa Solutions: Product Portfolio
  • Table 219. Qinecsa Solutions: Strategic Developments
  • Table 220. Sarjen Systems Pvt. Ltd.: Product Portfolio
  • Table 221. Clinevo Technologies: Product Portfolio
  • Table 222. Clinevo Technologies: Strategic Developments
  • Table 223. Cloudbyz: Product Portfolio
  • Table 224. Cloudbyz: Strategic Developments
  • Table 225. Biologit: Product Portfolio
  • Table 226. Biologit: Strategic Developments
  • Table 227. Available Customization Options
  • Table 228. Available Related Reports

LIST OF FIGURES

List of Figures

  • Figure 1. Pharmacovigilance Software Market Ecosystem
  • Figure 2. Pharmacovigilance Software Market: Key Stakeholders
  • Figure 3. Research Process
  • Figure 4. Key Secondary Sources
  • Figure 5. Breakdown of Primary Interviews: By Respondent Type, Designation and Region
  • Figure 6. Market Sizing and Growth Forecast Approach
  • Figure 7. Forecast Methodology
  • Figure 8. Data Triangulation
  • Figure 9. Executive Summary: Pharmacovigilance Software Market Size, 2024-2036 (USD Million)
  • Figure 10. Executive Summary: Pharmacovigilance Software Market, by Functionality, 2026 vs. 2036 (USD Million)
  • Figure 11. Executive Summary: Pharmacovigilance Software Market, by Component, 2026 vs. 2036 (USD Million)
  • Figure 12. Executive Summary: Pharmacovigilance Software Market, by Deployment Mode, 2026 vs. 2036 (USD Million)
  • Figure 13. Executive Summary: Pharmacovigilance Software Market, by Organization Size, 2026 vs. 2036 (USD Million)
  • Figure 14. Executive Summary: Pharmacovigilance Software Market, by End User, 2026 vs. 2036 (USD Million)
  • Figure 15. Executive Summary: Pharmacovigilance Software Market, by Geography, 2026 vs. 2036 (USD Million)
  • Figure 16. Executive Summary: Key Growth Strategies Adopted by Leading Players (January 2024-July 2026)
  • Figure 17. Executive Summary: Market Share of Key Players (2025)
  • Figure 18. Pharmacovigilance Software Market: Impact Analysis of Market Dynamics
  • Figure 19. Pharmacovigilance Software Market: Value Chain
  • Figure 20. Porter's Five Forces Analysis: Pharmacovigilance Software Market
  • Figure 21. Pharmacovigilance Software Market, by Functionality, 2026 vs. 2036 (USD Million)
  • Figure 22. Pharmacovigilance Software Market, by Component, 2026 vs. 2036 (USD Million)
  • Figure 23. Pharmacovigilance Software Market, by Deployment Mode, 2026 vs. 2036 (USD Million)
  • Figure 24. Pharmacovigilance Software Market, by Organization Size, 2026 vs. 2036 (USD Million)
  • Figure 25. Pharmacovigilance Software Market, by End User, 2026 vs. 2036 (USD Million)
  • Figure 26. Pharmacovigilance Software Market, by Geography, 2026 vs. 2036 (USD Million)
  • Figure 27. Pharmacovigilance Software Market: Country Market Size and Growth, 2026-2036
  • Figure 28. North America Pharmacovigilance Software Market Snapshot
  • Figure 29. Europe Pharmacovigilance Software Market Snapshot
  • Figure 30. Asia-Pacific Pharmacovigilance Software Market Snapshot
  • Figure 31. Latin America Pharmacovigilance Software Market Snapshot
  • Figure 32. Middle East & Africa Pharmacovigilance Software Market Snapshot
  • Figure 33. Pharmacovigilance Software Market: Competitive Structure
  • Figure 34. Key Growth Strategies Adopted by Leading Players (January 2024-July 2026)
  • Figure 35. Pharmacovigilance Software Market: Competitive Dashboard
  • Figure 36. Pharmacovigilance Software Market Share Analysis, by Key Player (2025)
  • Figure 37. Oracle Corporation: Financial Overview
  • Figure 38. Oracle Corporation: SWOT Analysis
  • Figure 39. Veeva Systems Inc.: Financial Overview
  • Figure 40. Veeva Systems Inc.: SWOT Analysis
  • Figure 41. ArisGlobal LLC: Company Overview
  • Figure 42. ArisGlobal LLC: SWOT Analysis
  • Figure 43. IQVIA Holdings Inc.: Financial Overview
  • Figure 44. IQVIA Holdings Inc.: SWOT Analysis
  • Figure 45. Ennov: Company Overview
  • Figure 46. Ennov: SWOT Analysis
  • Figure 47. AB Cube: Company Overview
  • Figure 48. AB Cube: SWOT Analysis
  • Figure 49. RxLogix Corporation: Company Overview
  • Figure 50. RxLogix Corporation: SWOT Analysis
  • Figure 51. Qinecsa Solutions: Company Overview
  • Figure 52. Qinecsa Solutions: SWOT Analysis
  • Figure 53. Sarjen Systems Pvt. Ltd.: Company Overview
  • Figure 54. Sarjen Systems Pvt. Ltd.: SWOT Analysis
  • Figure 55. Clinevo Technologies: Company Overview
  • Figure 56. Clinevo Technologies: SWOT Analysis
  • Figure 57. Cloudbyz: Company Overview
  • Figure 58. Cloudbyz: SWOT Analysis
  • Figure 59. Biologit: Company Overview
  • Figure 60. Biologit: SWOT Analysis
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!